

**RANBAXY LABORATORIES LIMITED**  
**Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 30 September 2012**  
(Rupees in millions except share data, per share data and if otherwise stated)

**PART I**

Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		Quarter ended 30 September	Quarter ended 30 June	Quarter ended 30 September	Nine months ended 30 September	Nine months ended 30 September	Year ended 31 December
		2012	2012	2011	2012	2011	2011
<b>1</b>	<b>Income from operations</b>						
	(a) Sales						
	- Within India (net of excise duty)	5,881.24	5,613.54	5,324.33	16,531.51	14,719.36	19,756.19
	- Outside India (refer to note 2)	20,632.67	26,127.06	14,907.87	78,677.03	47,460.48	79,822.26
	<b>Net sales (net of excise duty)</b>	<b>26,513.91</b>	<b>31,740.60</b>	<b>20,232.20</b>	<b>95,208.54</b>	<b>62,179.84</b>	<b>99,578.45</b>
	(b) Other operating income	396.55	544.31	802.48	1,664.27	1,853.68	2,594.74
	<b>Total income from operations (net)</b>	<b>26,910.46</b>	<b>32,284.91</b>	<b>21,034.68</b>	<b>96,872.81</b>	<b>64,033.52</b>	<b>102,173.19</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	5,300.39	5,506.97	5,255.74	15,150.94	17,389.20	23,198.43
	(b) Purchases of stock-in-trade	5,942.74	4,156.44	3,475.27	14,632.99	8,838.30	13,220.11
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(846.26)	597.78	(623.35)	(666.73)	(3,217.09)	(2,879.15)
	(d) Employee benefits expense (refer to note 4)	4,676.60	4,816.41	4,078.24	14,194.68	12,435.14	16,407.84
	(e) Depreciation, amortisation and impairment expense	816.33	782.69	787.59	2,397.71	2,258.85	3,940.17
	(f) Other expenses (refer to note 6)	8,342.24	12,094.05	6,974.44	34,991.53	20,474.69	35,250.49
	(g) Foreign exchange (gain)/loss others, net	(684.17)	2,504.23	550.26	870.00	56.34	962.23
	<b>Total expenses</b>	<b>23,547.87</b>	<b>30,458.57</b>	<b>20,498.19</b>	<b>81,571.12</b>	<b>58,235.43</b>	<b>90,100.12</b>
<b>3</b>	<b>Profit from operations before other income, finance costs and exceptional items (1-2)</b>	<b>3,362.59</b>	<b>1,826.34</b>	<b>536.49</b>	<b>15,301.69</b>	<b>5,798.09</b>	<b>12,073.07</b>
<b>4</b>	<b>Other income</b>	<b>660.59</b>	<b>697.25</b>	<b>285.86</b>	<b>1,964.99</b>	<b>1,011.87</b>	<b>1,444.35</b>
<b>5</b>	<b>Profit from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>4,023.18</b>	<b>2,523.59</b>	<b>822.35</b>	<b>17,266.68</b>	<b>6,809.96</b>	<b>13,517.42</b>
<b>6</b>	<b>Finance costs (refer to note 8)</b>	<b>(155.77)</b>	<b>1,648.66</b>	<b>1,512.03</b>	<b>1,679.50</b>	<b>2,155.17</b>	<b>3,037.38</b>
<b>7</b>	<b>Profit/(loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>4,178.95</b>	<b>874.93</b>	<b>(689.68)</b>	<b>15,587.18</b>	<b>4,654.79</b>	<b>10,480.04</b>
<b>8</b>	<b>Exceptional items</b>						
	- Settlement provision (refer to note 3a)	-	-	-	-	-	(26,480.00)
	- Gain/(loss) on foreign currency option derivatives, net (other than loans) (refer to note 3b)	3,933.25	(5,993.52)	(4,001.52)	1,386.89	(2,863.74)	(11,242.85)
	- Profit on sale of subsidiaries and long term investments, net	-	-	377.99	-	377.99	377.99
<b>9</b>	<b>Profit/(loss) from ordinary activities before tax (7+8)</b>	<b>8,112.20</b>	<b>(5,118.59)</b>	<b>(4,313.21)</b>	<b>16,974.07</b>	<b>2,169.04</b>	<b>(26,864.82)</b>
<b>10</b>	<b>Tax expense, net</b>	<b>541.55</b>	<b>682.83</b>	<b>255.99</b>	<b>2,598.62</b>	<b>1,222.60</b>	<b>1,969.34</b>
<b>11</b>	<b>Net profit/(loss) for the period (9-10)</b>	<b>7,570.65</b>	<b>(5,801.42)</b>	<b>(4,569.20)</b>	<b>14,375.45</b>	<b>946.44</b>	<b>(28,834.16)</b>
<b>12</b>	<b>Share in loss of associate, net</b>	<b>-</b>	<b>39.81</b>	<b>48.01</b>	<b>161.31</b>	<b>48.01</b>	<b>65.90</b>
<b>13</b>	<b>Minority interest</b>	<b>28.92</b>	<b>16.02</b>	<b>28.59</b>	<b>62.02</b>	<b>68.01</b>	<b>97.23</b>
<b>14</b>	<b>Net profit/(loss) after tax, minority interest and share in loss of associate (11-12-13)</b>	<b>7,541.73</b>	<b>(5,857.25)</b>	<b>(4,645.80)</b>	<b>14,152.12</b>	<b>830.42</b>	<b>(28,997.29)</b>
<b>15</b>	<b>Paid - up equity share capital (Face value of Rs. 5 each)</b>	<b>2,111.32</b>	<b>2,110.56</b>	<b>2,107.53</b>	<b>2,111.32</b>	<b>2,107.53</b>	<b>2,110.00</b>
<b>16</b>	<b>Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>26,511.19</b>
<b>17</b>	<b>Earnings/(Loss) per share (Rs.) - not annualised</b>						
	Basic	17.87	(13.89)	(11.02)	33.55	1.97	(68.81)
	Diluted	17.82	(13.89)	(11.02)	33.43	1.96	(68.81)

See accompanying notes to the consolidated unaudited financial results

**PART II**

Select information for the quarter and nine months ended 30 September 2012

Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		Quarter ended 30 September	Quarter ended 30 June	Quarter ended 30 September	Nine months ended 30 September	Nine months ended 30 September	Year ended 31 December
		2012	2012	2011	2012	2011	2011
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
<b>1</b>	<b>Public shareholding #</b>						
	- Number of shares	145,030,478	145,005,743	145,462,453	145,030,478	145,462,453	145,827,559
	- Percentage of shareholding	34.35%	34.35%	34.51%	34.35%	34.51%	34.56%
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non - encumbered						
	- Number of shares	268,711,323	268,711,323	268,711,323	268,711,323	268,711,323	268,711,323
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	63.64%	63.66%	63.75%	63.64%	63.75%	63.68%

# Aggregate public shareholding as defined under Clause 40A of the Listing Agreement (excludes shares held by Promoters and Promoter Group Shareholding and Global Depository Shares)

Particulars	(Unaudited)
	Quarter ended 30 September 2012
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	4
Disposed off during the quarter	4
Remaining unresolved at the end of the quarter	Nil

**RANBAXY LABORATORIES LIMITED**

**Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 30 September 2012**

(Rupees in millions except share data, per share data and if otherwise stated)

Notes:

- 1 The consolidated unaudited financials results of Ranbaxy Laboratories Limited ("the Company"), its subsidiaries and an associate (collectively known as "the Group") are prepared in accordance with requirements of the Accounting Standard ("AS") 21 "Consolidated Financial Statements" and AS 23 "Accounting for Investments in Associates in Consolidated Financial Statements" prescribed by Companies (Accounting Standards) Rules, 2006 (as amended).
- 2 Sales outside India for all periods presented include significant sales relating to First-To-File (FTF) products in the United States of America ("USA").
- 3 a) The Company is negotiating towards a settlement with the Department of Justice ("DOJ") of the USA for resolution of potential civil and criminal allegations by the DOJ. Accordingly, the Company had recorded a provision of Rs. 26,480 (USD 500 million) in the year ended 31 December 2011, which the Company believes will be sufficient to resolve all potential civil and criminal liability.  
Any gain/loss on account of changes in exchange rate and related interest expense is presented in the relevant line item.  
b) The amount represents foreign exchange gain/ (loss), net, on foreign currency option derivatives taken during previous years (other than option derivatives relating to loans) which are accounted in accordance with Accounting Standard 30, "Financial Instruments: Recognition and Measurement".
- 4 On the basis of a legal advice, the Company is of the view that the appointment and payment of remuneration to Mr. Arun Sawhney, CEO and Managing Director for the year ended 31 December 2011 is in accordance with the conditions stipulated under the Notification no. GSR 534(E) dated 14 July 2011 read with the clarification dated 16 August 2012 issued by the Ministry of Corporate Affairs. In view of this, the earlier periods qualification of the Auditors in this regard stands resolved.
- 5 On exercise of Employees Stock Options, 208,854 equity shares have been allotted on 11 October 2012. The total number of Employees Stock Options outstanding as at 30 September 2012 were 6,873,972, out of which 4,483,465 have vested. The entitlement of shares on exercise of stock options granted on or before 3 October 2002 would increase in the proportion of 3:5, keeping in view the issue of bonus shares on 11 October 2002.
- 6 The Company has accrued an expense as claims and contractual payment towards a portion of profit payable to another party in relation to sales of a product. Claims and contractual payment expense included in 'Other expenses' qualifies for a separate line item disclosure in accordance with clause 41 of the Listing Agreement as the same is more than 10% of total expenses for the quarter ended 30 June 2012 and nine months period ended 30 September 2012. However, the same has not been disclosed as a separate line item in view of certain terms of agreement with the party. This has a reference to the qualification made in the audit report for the year ended 31 December 2011 and in the review reports for all interim periods of the current financial year of the Company.
- 7 There are two reportable business segments i.e. 'Pharmaceuticals' and 'others'. However, as the management considers the activities of the 'others' segment as immaterial, segment disclosures have not been given.
- 8 Finance cost includes exchange differences arising from foreign currency borrowings, to the extent that these are regarded as an adjustment to interest costs. The aggregate amount of such exchange difference for all periods presented is set out below

Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Quarter ended 30 September 2012	Quarter ended 30 June 2012	Quarter ended 30 September 2011	Nine months ended 30 September 2012	Nine months ended 30 September 2011	Year ended 31 December 2011
Foreign exchange (gain)/loss	(554.98)	1,165.41	1,358.40	420.15	1,691.28	2,269.51


- 9 Pursuant to the provisions of the Listing Agreement, the management has decided to publish consolidated unaudited financial results in the newspapers. However, the standalone unaudited financial results will be made available on the Company's website at [www.ranbaxy.com](http://www.ranbaxy.com) and also on the websites of the Bombay Stock Exchange Limited (BSE) ([www.bseindia.com](http://www.bseindia.com)) and the National Stock Exchange of India limited (NSE) ([www.nseindia.com](http://www.nseindia.com)).

Information of standalone unaudited financial results in terms of Clause 41(VI) (b) of the Listing Agreement is as under:

Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Quarter ended 30 September 2012	Quarter ended 30 June 2012	Quarter ended 30 September 2011	Nine months ended 30 September 2012	Nine months ended 30 September 2011	Year ended 31 December 2011
Net sales	14,280.38	14,727.50	13,496.24	47,110.16	36,451.03	74,758.96
Profit/(loss) from ordinary activities before tax	5,521.92	(9,256.66)	(4,301.96)	4,537.57	(3,383.49)	(30,486.70)
Net profit/(loss) from ordinary activities after tax	5,521.92	(9,256.66)	(4,391.96)	4,537.57	(3,417.28)	(30,520.49)

- 10 Pursuant to amendments made to the Listing Agreement in respect of format of disclosure of financial results, the consolidated unaudited financial results for the quarter and nine months ended 30 September 2012 has been prepared in the revised format. Accordingly, the previous year/periods figures have also been reclassified to conform to the current period's classification.
- 11 The above results were reviewed by the Audit Committee on 7 November 2012, and approved by the Board of Directors at their meeting held on 8 November 2012 and have undergone a "Limited Review" by the Statutory Auditors of the Company. The review report of the Statutory Auditors containing the reservations is being filed with the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited and is also available on the Company's website at [www.ranbaxy.com](http://www.ranbaxy.com).

By order of the Board

  
 Arun Sawhney  
 CEO and Managing Director

Place: Gurgaon  
Date: 8 November 2012

Regd. Office : A-41, Industrial Area Phase VIII A, Sahibzada Ajit Singh Nagar (Mohali) - 160 071 (Punjab)  
Website: <http://www.ranbaxy.com>